Liquidia (NASDAQ:LQDA) Trading Down 4.7%

Shares of Liquidia Co. (NASDAQ:LQDA) were down 4.7% during trading on Tuesday . The company traded as low as $12.70 and last traded at $12.70. Approximately 412,124 shares changed hands during trading, a decline of 53% from the average daily volume of 873,157 shares. The stock had previously closed at $13.33.

Analysts Set New Price Targets

A number of analysts have recently commented on LQDA shares. HC Wainwright reissued a “buy” rating and set a $32.00 target price on shares of Liquidia in a research note on Wednesday, May 15th. Needham & Company LLC reissued a “buy” rating and set a $28.00 target price on shares of Liquidia in a research note on Monday, June 3rd. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the company. According to data from MarketBeat.com, Liquidia presently has a consensus rating of “Moderate Buy” and a consensus price target of $21.00.

Liquidia Stock Performance

The company has a market cap of $956.28 million, a PE ratio of -8.09 and a beta of 0.25. The firm’s 50 day moving average is $13.17 and its 200-day moving average is $12.96.

Liquidia (NASDAQ:LQDA) last posted its earnings results on Monday, May 13th. The company reported ($0.54) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.22). The firm had revenue of $2.97 million during the quarter, compared to analyst estimates of $4.31 million. Liquidia had a negative net margin of 674.42% and a negative return on equity of 177.83%. On average, analysts predict that Liquidia Co. will post -1.26 EPS for the current year.

Insider Buying and Selling at Liquidia

In other news, CFO Michael Kaseta sold 3,136 shares of the company’s stock in a transaction that occurred on Friday, April 12th. The shares were sold at an average price of $14.58, for a total value of $45,722.88. Following the transaction, the chief financial officer now directly owns 315,045 shares in the company, valued at approximately $4,593,356.10. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, CFO Michael Kaseta sold 3,136 shares of the company’s stock in a transaction that occurred on Friday, April 12th. The shares were sold at an average price of $14.58, for a total value of $45,722.88. Following the transaction, the chief financial officer now directly owns 315,045 shares in the company, valued at approximately $4,593,356.10. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Roger Jeffs sold 8,360 shares of the company’s stock in a transaction that occurred on Friday, April 12th. The stock was sold at an average price of $14.58, for a total transaction of $121,888.80. Following the completion of the transaction, the chief executive officer now owns 826,985 shares in the company, valued at $12,057,441.30. The disclosure for this sale can be found here. Insiders have sold 18,653 shares of company stock worth $270,409 in the last ninety days. 31.60% of the stock is owned by insiders.

Institutional Investors Weigh In On Liquidia

Several large investors have recently added to or reduced their stakes in LQDA. Aigen Investment Management LP purchased a new stake in Liquidia during the 3rd quarter worth approximately $80,000. Beryl Capital Management LLC purchased a new stake in Liquidia during the 3rd quarter worth approximately $3,135,000. Corton Capital Inc. increased its stake in Liquidia by 14.2% during the 3rd quarter. Corton Capital Inc. now owns 23,440 shares of the company’s stock worth $149,000 after buying an additional 2,921 shares during the period. Kynam Capital Management LP increased its position in shares of Liquidia by 21.8% in the 3rd quarter. Kynam Capital Management LP now owns 2,000,000 shares of the company’s stock valued at $12,680,000 after purchasing an additional 357,756 shares during the last quarter. Finally, Kerrisdale Advisers LLC purchased a new stake in shares of Liquidia in the 3rd quarter valued at approximately $509,000. 64.54% of the stock is owned by hedge funds and other institutional investors.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).